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Assessment of Optimal Virus-Mediated Growth
Factor Gene Delivery for Human Cutaneous Wound
Healing Enhancement
Marı´a J. Esca´mez1, Marta Carretero2, Marta Garcı´a1, Lucı´a Martı´nez-Santamarı´a1, Isabel Mirones2,
Blanca Duarte2, Almudena Holguı´n1, Eva Garcı´a3, Vero´nica Garcı´a3, Alvaro Meana3, Jose´ L. Jorcano1,2,
Fernando Larcher2 and Marcela Del Rı´o1
Using a recently described skin-humanized model based on the engraftment of human bioengineered skin
equivalents onto immunodeficient mice, we compared the efficacy of different in vivo gene transfer strategies
aimed at delivering growth factors to promote skin wound healing. The approaches involving transient delivery
of keratinocyte growth factor (KGF) to wounds performed in the engrafted human skin included (1) KGF gene
transfer by intradermal adenoviral injection; (2) KGF gene transfer by adenoviral vector immobilized in a fibrin
carrier; and (3) KGF-adenoviral gene-transferred human fibroblasts embedded in a fibrin matrix. All delivery
systems achieved KGF protein overproduction at the wound site, with a concomitant re-epithelialization
enhancement. However, although direct gene delivery strategies exhibited variability in terms of the number of
successfully transduced humanized mice, the use of genetically modified fibroblast-containing matrix as an
in situ protein bioreactor was highly reproducible, leading to a significant improvement of the overall healing
process. This latter approach appeared to be the most reliable means to deliver growth factors to wounds and
also avoided the potential danger of scoring cases of faulty administration as therapeutic failures and direct
exposure to viral vectors. The combined use of cell and gene therapy appears a robust tool to aid healing in a
clinical context.
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INTRODUCTION
In the past years, a growing incidence of vascular diseases has
been detected in many developed countries. In addition,
concomitant increases in other pathologies such as diabetes,
together with increased life expectancy, are likely to make
vascular disorders even more prevalent in the near future.
Vascular diseases often lead to chronic wounds in the skin
that are associated with diminished quality of life, frequent
hospitalizations, and increased morbidity and mortality
(Franks et al., 1994; Woodall, 1996; Kaplan and Pennington,
2003). Chronic wounds are a critically important medical
problem, and despite considerable advances in elucidating
the molecular basis of wound repair, attempts at developing
new therapies have been disappointing and their management
is still a formidable challenge.
At the preclinical level, various strategies have been
explored in an attempt to enhance wound healing. Among
these, the use of growth factors has been shown to have
considerable potential (Aukerman and Pierce, 1997; Chand-
ler and Sosnowski, 2004). Growth factors that play a role in
normal wound healing and, in addition, are often deficient or
inactive in chronic wounds have been highlighted as
attractive therapeutic agents (Pierce and Mustoe, 1995; Beer
et al., 1997). Among these factors are platelet-derived growth
factor, EGF, IGF-1, transforming growth factor-a and trans-
forming growth factor-b, and members of the fibroblast
growth factor family, including keratinocyte growth factor
(KGF; fibroblast growth factor 7) (Mustoe et al., 1987, 1991;
McGee et al., 1988; Nanney, 1990; Pierce et al., 1992, 1994,
1995; Erdag et al., 2004; Geer et al., 2005). However,
although some of them induced significant enhancement of
wound repair in animal studies (Pierce and Mustoe, 1995),
the clinical success of growth factors administered as
recombinant proteins has been disappointing (Pierce and
Mustoe, 1995; Braddock et al., 1999). The most plausible
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explanation is ineffective delivery of the protein to the cells
involved in wound repair due to elevated matrix metallopro-
teinases and other myeloid cell-derived proteases that
downgrade their already short half-lives, thus failing to
maintain local protein levels above the therapeutic threshold
(Trengove et al., 1999; Yager and Nwomeh, 1999). Taking
into account these limitations, gene therapy has drawn
significant attention as an alternative for wound healing
therapy (Davidson et al., 1999; Chandler and Sosnowski,
2004; Carretero et al., 2006). In fact, the promising results of
the first gene therapy clinical trial for wound healing using
first-generation adenoviral vectors have been recently re-
ported by Margolis et al. (2007).
In this study, we have searched for an optimal, clinically
meaningful growth factor delivery system for wound healing
managing purposes. To investigate the suitability of different
gene transfer approaches, we performed a comparative study
using a panel of in vivo and ex vivo strategies in the skin-
humanized mouse model. In contrast to most studies that
assessed the graft-take performance immediately after grafting
as an estimation of wound healing success (Eming et al., 1995,
1998; Del Rio et al., 1999; Supp et al., 2000a, b; Hamoen and
Morgan, 2002; Supp and Boyce, 2002), in our study the
healing process was monitored on full-thickness wounds
created in an already engrafted and stable human skin.
Assessment was carried out by analyzing the healing response
after delivery of KGF, a growth factor with a prominent role in
wound re-epithelialization (Werner, 1998). Protocol reliabil-
ity, transgene expression/localization, and induced biological
responses were analyzed for each delivery system.
RESULTS
Wound healing in permanently KGF-expressing human skin
We have previously described a skin-humanized mouse
system suitable for preclinical human wound healing studies
(Escamez et al., 2004). The efficacy of the healing process
was evaluated in transgenic human skin constitutively over-
expressing human KGF (hKGF) (KGF-transgenic (KGF-tg))
from the epidermis as a reference system (Figure S1a).
Transgenic human skin was regenerated on mice by grafting
a bioengineered skin composed of ex vivo retrovirally
transduced human keratinocytes as the epidermal compart-
ment of an artificial skin (Del Rio et al., 2002; Escamez et al.,
2004; Gache et al., 2004, Larcher et al., 2007).
The retroviral construct used, encoding a KGFiresGFP
bicistronic cassette, is shown in Figure 1a. Under these
experimental conditions, hKGF is expressed by all the different
epidermal layers due to the ubiquitous transgene expression
when driven by a long terminal repeat promoter (Del Rio
et al., 2002; Serrano et al., 2003). Fluorescence due to the
sustained green fluorescent protein (GFP) expression was thus
observed in the whole grafted area (Figure 1b, right panels) of
all KGFiresGFP- and GFP-grafted animals (n¼ 6 for each
group). At 12 weeks after grafting, a 2mm circular excisional
wound was created in the center of both control GFP- and
KGF-expressing human skin grafts (GFP-tg and KGF-tg human
skin) (Figure 1b). We have previously shown that when a
neutral gene such as GFP is expressed in our gene-targeted
skin-humanized mouse model, where both keratinocytes and
fibroblasts are of human origin, the healing process recapitu-
lates the main features and kinetics of native human wound
healing (Escamez et al., 2004). In contrast to that observation
in mouse skin, wound contraction in the grafted human skin is
barely apparent (Figure S2). Macroscopic examination of the
KGF-tg human skin 3 days post-wounding revealed a
significant enhancement of wound closure when compared
to GFP-tg human skin grafts (Figure 1c). The re-epitheliali-
zation process after wounding was monitored by histological
analysis (hematoxylin and eosin staining) across the full
extension of the wounds, and measurements taken at the
wound center confirmed faster re-epithelialization in KGF-tg
human skin (Figure 1d). The percentage of wound closure
increased from 23.3±2.9% in GFP-tg to 31.7±2.8% in
KGF-tg skin wounds (Po0.05). Consistently, the length of the
epithelial migratory tongue increased from 0.6±0.07mm in
GFP-tg to 0.8±0.03mm in KGF-tg skin wounds (Po0.05).
The results obtained in transgenic human skin constitutively
overexpressing hKGF were used then as a reference for the
targeting strategies described below.
In vivo gene delivery by injection of adenoviral vector
suspension
In the first approach, we assessed the effects of hKGF
delivered after intradermal injection of an adenoviral
suspension in wounded normally regenerated human skin
(Figure S1b). Twelve weeks after grafting, the regenerated
human skin was wounded with a 2mm biopsy punch and
3109 plaque-forming unit (PFU) of purified adenovirus
encoding hKGF/GFP in a bicistronic cassette (Ad-KGFir-
esGFP) or GFP (Ad-GFP) (Figure 2a) was injected around the
wound (n¼12 for each group). At 1 and 3 days after
injection, GFP fluorescence was found locally restricted to
the sites of injection (Figure 2b and c) in confirmed
transduced grafts. A clear correlation was found between
the area of fluorescence due to the expression of GFP/hKGF
(and further confirmed by GFP immunohistochemistry) and
the healing performance of the gene-targeted skin (data not
shown). Thus, when robust gene transfer was achieved, an
improvement in wound closure was clearly observed macro-
scopically and further confirmed by quantitative histological
analysis of the migrating epidermis (Figure 2c and d).
However, although re-epithelialization showed a tendency
to increase in Ad-KGFiresGFP-injected animals (wound
closure increased from 25.0±4.0 in Ad-GFP control animals
to 45.2±10.1 in Ad-KGFiresGFP, P40.05) and the length of
the epithelial migratory tongue increased from 0.8±0.1mm
in Ad-GFP control animals to 1.3±0.3mm in Ad-KGFir-
esGFP-injected animals (P40.05), the method proved to be
unreliable both in terms of the number of successfully
targeted animals versus the number of total treated animals
and re-epithelialization efficiency (Table 1).
In vivo gene delivery by adenoviral vector-immobilized
application
In the second approach, both GFP- and KGF-encoding
adenoviral vectors were immobilized in a fibrin carrier
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(Schek et al., 2004) and applied immediately after wounding
(Figure S1b). The infection levels over time have been
previously correlated with the fibrin concentration. Thus, a
fibrinogen concentration of 0.5mgml1 that was previously
shown to allow a high rate of vector diffusion was chosen
(Schek et al., 2004). Fibrin gels containing 3 109 PFU of
purified Ad-KGFiresGFP or Ad-GFP (nX8 for each group)
were used to individually cover 2mm wounds and the
surrounding area (Figure 3a and b). The immobilized
adenovirus particles remained infective and the proportion
of successfully targeted animals, as determined by direct GFP
fluorescence, was higher than that achieved with the
adenoviral injection method (Table 1). Re-epithelialization
rose significantly according to wound closure and length of
the epithelial migratory tongue measurements (22.3±4.0%
in Ad-GFP fibrin gels to 54.0±10.9% in Ad-KGFiresGFP and
0.6±0.1mm in Ad-GFP fibrin gels to 1.1±0.2mm in Ad-
KGFiresGFP, respectively) (Figure 3c and Table 1).
Transgene expression analysis
To further assess the intrinsic wound healing-promoting
abilities of each targeting system, we performed a comparative
study of the differential transgene expression localization. An
immunohistochemical analysis of GFP expression in 3-day
wounds allowed us to identify gene-targeted cells. As
predicted, ex vivo (retrovirally based) gene transfer of a long
terminal repeat-driven KGFiresGFP transgene to keratinocytes
led to in vivo expression in basal and suprabasal epidermal
strata (Figure 4a). In contrast, the two in vivo gene transfer
strategies using the adenoviral vector showed remarkable
differences in transgene expression localization. Although in
the adenovirus injection approach the targeted cells mostly
comprised a variety of mesenchymal cells, the adenovirus in
the fibrin carrier strategy targeted mainly cells of epidermal
origin, including the epidermal leading edge (Figure 4b and c,
respectively).
Tissue KGF protein overproduction was confirmed for the
different strategies by ELISA immunodetection (Table 1). The
higher levels achieved through retroviral gene transfer
(3.1±0.4 pg of KGF per ng total protein) and adenoviral
injections (3.5±2.5 pg of KGF per ng total protein) (Table 1)
are very likely related to the amount of targeted tissue
harvested for protein extraction. Thus, the lower KGF in the
adeno/gel-treated wounds (0.7±0.6 pg of KGF per ng total
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Figure 1. Enhancement of wound closure in human skin overexpressing KGF by ex vivo retroviral gene transfer to keratinocytes (KGF-tg human skin).
(a) Schematic representation of the bicistronic pLZR-KGF-ires-GFP recombinant replication-deficient retroviral vector. (b and c) A representative wound healing
experiment performed on human tg-skin excisionally injured with 2mm biopsy punches at 12 weeks after transplantation. Stereo-microphotographs of a wound
from GFP-tg and KGF-tg human skin on day 0 (b; bar¼2mm) and day 3 post-wounding (c; bar¼1mm) under white light illumination (left panels) and
epifluorescence illumination (right panels). GFP fluorescence delimits the grafted area as observed on day 0. Dotted white lines delimit the wound edge and
evidence an improvement in wound closure at 3 days post-wounding in the KGF-tg human skin. (d) Composite pictures of the center of 3-day wounds
stained with H&E taken from GFP-tg and KGF-tg skins. Black lines underline the basal epidermal layer and the migratory tongue. KGF overexpression
accelerates the wound re-epithelialization as evidenced by a reduction of the epidermal gap distance (double arrowhead). Bar¼ 0.5mm. CMV,
cytomegalovirus; H&E¼ hematoxylin and eosin; LTR, long terminal repeat.
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protein) is probably due to the fact that the adenovirus
delivered from the gel targets only a restricted number of
epidermal cells not shielded by the scab or the stratum
corneum. The targeted cells are, however, those proficient in
the healing process.
In vivo protein delivery by ex vivo adenoviral vector-transduced
fibroblasts
A third strategy was explored. In this case, hKGF protein was
delivered from ex vivo Ad-KGFiresGFP-transduced fibroblasts
that were, in turn, embedded in a fibrin matrix and used to
treat the wound (Figure S1b). In contrast to the two previous
methods based on direct adenovirus delivery, the cell-
mediated delivery system did not depend on in vivo cell
transduction but rather on the direct delivery of the therapeutic
protein from gene-targeted fibroblasts (Figure 5a). Thus, fibrin
gels containing 1 106 Ad-KGFiresGFP- or Ad-GFP-modified
human fibroblasts (n¼8 for each group) were placed to cover
each skin wound and the surrounding tissue (Figure 5b). KGF
released to the supernatant by fibroblasts inside the fibrin gel
was determined through ELISA. A 104-fold increase between
KGF-transduced and control GFP fibroblasts was obtained
(874ng KGF per ml from Ad-KGF fibroblasts versus 0.04 ng
KGF per ml from Ad-GFP). As predicted, direct GFP
fluorescence was readily detected above the wound bed
inside the fibrin gel in all treated animals (Figure 5c and
Table 1), and transfer of exogenous KGF to the wound was
confirmed by ELISA (Table 1). In addition, re-epithelialization
increased significantly as wound closure increased from
20.7±4.7% in animals treated with fibrin gels containing
GFP-expressing fibroblasts to 41.2±7.5% in hKGF/GFP-
expressing fibroblasts (Po0.05) (Figure 5d and Table 1) and
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Figure 2. Enhancement of the closure of a wound overexpressing KGF by in vivo adenoviral vector suspension via intradermal injection. (a) Schematic
representation of the generation of the KGF bicistronic serotype 5 replication-defective adenovirus vector containing the CMV promoter by homologous
recombination. (b and c) A representative wound healing experiment performed on human non-genetically modified skin excisionally injured with 2mm biopsy
punches at 12 weeks after transplantation. In vivo adenoviral transfer was performed via intradermal injection of either Ad-GFP or Ad-KGFiresGFP around the
wound edge. Stereo-microphotographs (b) of a 1-day injected wound and (c) of 3-day Ad-GFP- and Ad-KGFiresGFP-overexpressing wounds under white light
illumination (left panels) and epifluorescence illumination (right panels). GFP fluorescence is slightly visible at 1-day post-wounding and increases at day 3,
restricted to the area surrounding the wound edge. Dotted white lines delimit the wound edge and evidence an improvement of the wound re-epithelialization
at 3-day post-wounding. Bar¼ 1mm. (d) H&E staining (composite picture) of the center of 3-day wounds from GFP and KGF adenovirus-injected wounds.
Black lines underline the basal epidermal layer and the migratory tongue. KGF overexpression accelerates the wound re-epithelialization as evidenced by
a reduction of the epidermal gap distance (double arrowhead). Bar¼ 0.5mm. CMV, cytomegalovirus; H&E¼hematoxylin and eosin; LTR, long terminal
repeat.
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the length of the epithelial migratory tongues increased from
0.5±0.1mm in Ad-GFP fibrin gels to 0.8±0.1mm in Ad-
KGFiresGFP, Po0.05 (Table 1). Healing of skin-humanized
mice treated with this strategy was further assessed at 6 and 12
days post-wounding. As shown in Figure 5e, the residual
epithelial gap was dramatically reduced in 6-day wounds
treated with KGF-secreting fibroblasts embedded in fibrin
gels. Wound closure, defined as complete re-epithelialization,
was observed in all treated and control wounds by 12 days
after wounding (Figure 5e). Persistence of GFP-positive
fibroblasts was evidenced at 6 but not at 12 days after
wounding (Figure S3).
Assessment of hKGF-mediated effects on different in vivo
delivery approaches
Considering the known promoting effects of KGF on
epidermal growth, we analyzed a quantitative surrogate
marker of the KGF response for each of the different targeting
approaches. The proliferative status in 3-day wounds handled
with the different strategies was evaluated by BrdU incor-
poration (Figure 6). Consistent with previous results (Mustoe
et al., 1991; Staiano-Coico et al., 1993; Werner, 1998; Erdag
et al., 2004; Geer et al., 2005), the proliferative response was
significantly increased in the migrating epidermal tongue and
at the margin of wounds in KGF-tg human skin. A statistically
significant increase in the proliferative response was also
found in the epidermal tongue and at the margin of KGF-
treated wounds following intradermal injection of the
adenoviral vector, immobilized Ad-KGFiresGFP particles, or
Ad-KGFiresGFP-modified fibroblasts (Figure 6 and Table 1).
DISCUSSION
Treatment of chronic wounds by transient in vivo gene
therapy requires the use of reproducible, ‘‘standardizable,’’
and safe protocols. In this study, we compared different
methods, including those currently employed in clinical trials
and novel approaches. In our system, two skin repair
processes take place. Immediately after grafting, the regen-
eration of a human skin in vivo occurs. After stable
engraftment, a small full-thickness wound created on a
mature quiescent human skin closes. Although most wound
healing studies involving grafting of skin equivalents rely on
graft-take performance as a rough estimate of wound healing
success (Eming et al., 1995, 1998; Del Rio et al., 1999; Supp
et al., 2000a, b; Hamoen and Morgan, 2002; Supp and
Boyce, 2002), we focused on the actual wound closure of
full-thickness wounds created in already engrafted and stable
human skin. In spite of its reliability as a steady and
Table 1. Comparative performance of KGF delivery strategies
Performance
Biological effects in successfully transduced animals
Re-epithelialization3
Strategy
Wound GFP expression
(% of positive animal
(direct GFP
fluorescence))1
Wound KGF overexpression
in KGF successfully
transduced animals (ELISA)2
(pg KGF per ng total protein) % Wound closure
Length of the
migratory
tongue (mm)
Fold increase in
the proliferation
index4
First approach: in vivo gene
delivery by adenoviral vector
suspension
58 3.5±2.5 GFP=25.0±4.0
KGP=45.2±10.1
P40.05
GFP=0.8±0.1
KGP=1.3±0.3
P40.05
1.9
Second approach: in vivo
gene delivery by immobilized
adenoviral vector
69 0.7±0.6 GFP=22.3±4.0
KGF=54.0±10.9
Po0.05
GFP=0.6±0.1
KGP=1.1±0.2
Po0.05
1.8
Third approach: in vivo
protein delivery by ex vivo
adenovirus-transduced
fibroblasts
0 (100)5 1.1
(GFP=0.04 ng KGFml1
KGF=874 ng KGFml1)6
GFP=20.7±4.7
KGF=41.2±7.5
Po0.05
GFP=0.5±0.1
KGP=0.8±0.1
Po0.05
2.5
GFP, green fluorescent protein; KGF, keratinocyte growth factor.
1The percentage of positive animals is calculated as 100(total number of GFP-positive animals/total number of treated animals).
2ELISA immunodetection method was used to measure KGF protein overproduction in treated tissue samples compared to controls (o31.2 pgml1).
3The re-epithelialization across each wound site was analyzed. The percentage of wound closure was calculated by the following formula: 100[(wound
diameterepidermal gap)/wound diameter]. Values were expressed as mean±SD. The length of the epithelial migratory tongue was calculated by the
following formula: 100[(wound area at 0 hourwound area at 24 hours)/wound area at 0 hour]. Values were expressed as mean±SD in mm. The analysis of
re-epithelialization was performed only using the successfully targeted wounds.
4The increase of the proliferation index was calculated as the ratio between the % of total BrdU-positive nuclei (% of total BrdU-positive nuclei in the
tongue+% of total BrdU-positive nuclei in the margin) between controls and treated animals.
5No fluorescent/GFP-positive cells are observed in the regenerated human skin of animals treated with fibrin gels containing ex vivo adenovirus-transduced
fibroblasts (0% transduction). However, in all treated animals, fibroblasts embedded in the fibrin gel covering the wound are fluorescent/GFP positive
(100%).
6ELISA immunodetection method was used to measure KGF protein overproduction in 2ml of 24-hour supernatants recovered from fibrin gels containing
106 fibroblasts transduced with either Ad-GFP or Ad-KGF.
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reproducible delivery system, the retroviral approach invol-
ving autologous grafting of ex vivo permanently modified
keratinocytes cannot be considered a clinically relevant
approach for a transient condition such as wound healing. In
addition, the persistent delivery of a particular growth factor
over time may be unnecessary and likely to cause untoward
effects. Therefore, the former approach was only used as a
preclinical reference platform.
With reference to the clinically relevant approaches
tested, we found that the adenovirus-mediated gene delivery
systems lack adequate reproducibility. Thus, the variable
proportion of targeted grafts/animals and the uncertain
localization of gene expression revealed by GFP immunode-
tection indicate that the adenovirus injection approach,
although effective in some animals, failed in others,
conceivably because of this particular method of vector
administration. Although the dose and route (intradermal) of
administration of the vector and even the operator remain
constant, it is virtually impossible to reproduce the number,
type, and localization of infected cells from one human graft
to another. The differences in the percentage of re-epitheliali-
zation between transduced animals are probably due to
differences between the relative localization of transduced/
secreting cells (see below) and the cells that are the target of
KGF biological effects (keratinocytes at the wound edge). This
method would potentially create a concentration gradient for
KGF. In some cases, for example, when the modified/
secretory cells are localized in the deeper dermis, the
concentration of KGF at the wound edge may not reach the
threshold required for biological activity.
KGF gene transfer through adenovirus immobilized in a
biocompatible and degradable fibrin carrier enhances repro-
ducibility in terms of the number of animals clinically
transduced. This higher reproducibility of the virus-immobi-
lized system may be explained partly by greater stability in
vector delivery, as a protective effect of fibrin on adenoviral
vector preparations against serum proteins has been reported
recently (Jensen and Johnson, 1994; Doukas et al., 2001;
Ochiya et al., 2001). This effect would prevent the rapid loss
of infectivity of the vector, an inevitable drawback when
vector suspensions are injected. Furthermore, the potential to
use the gel to match the wound site allows a more localized-
controlled gene transfer. Our results clearly indicate that the
adenovirus-immobilized system improves reliability and
Human skin
KGF
GFP
KGF
Human skin Human skin
Figure 3. Enhancement of the closure of a wound overexpressing KGF by in
vivo application of adenoviral vectors immobilized in a fibrin carrier.
(a) Appearance of a transduced fibroblast-containing fibrin gel covering a
wound and the surrounding area (left panel; bar¼0.5 cm) and held in place
with adhesive Tegaderm (right panel; bar¼ 1 cm). (b) Stereo-
microphotographs of a 3-day wound treated with the immobilized Ad-KGF
(3109 PFU), after Tegaderm has been removed, under white light
illumination (left panel) and epifluorescence illumination (right panel).
Fluorescence due to the acute GFP expression is observed around the wound
edge and is restricted to the surrounding skin area covered by the gel. Dotted
white lines delimit the wound edge. Bar¼ 0.5mm. (c) H&E staining
(composite pictures) of the center of 3-day wounds from animals treated with
Ad-GFP and Ad-KGFiresGFP immobilized in a fibrin carrier. Black lines
underline the basal epidermal layer and the migratory tongue. KGF
overexpression accelerates the wound re-epithelialization as evidenced by a
reduction of the epidermal gap distance (double arrowhead). Bar¼0.5mm.
H&E¼ hematoxylin and eosin.
Figure 4. Comparative analysis of transgene expression and localization
(GFP immunostaining) for the different cutaneous gene targeting strategies.
Composite pictures of 3-day wounds are shown in all panels. Black lines
underline the basal epidermal layer and the migratory tongue. (a) Ex vivo gene
transfer of keratinocytes regenerated a GFP-positive epithelium in basal and
suprabasal strata in the whole grafted area. (b) In vivo gene transfer by
intradermal injection of adenoviral suspension targeted a variety of
mesenchymal cells. Higher magnification photographs in the inset show
GFP-positive fibroblasts (left inset) and GFP-positive endothelial cells as a part
of the wall of blood vessels (right inset). (c) In vivo gene transfer by fibrin
carrier-immobilized adenovirus is able to transduce epidermal cells in basal
and suprabasal strata in the epithelium surrounding the wound, including
those that are part of the migrating tongue. GFP-positive cells of mesenchymal
origin are also observed. Bar¼ 0.5mm.
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targets a larger number of cells that are part of the leading
epidermal edge or are located nearby.
In situ wound KGF protein delivery through ex vivo
genetically modified fibroblasts assembled as part of a ready-
to-go fibrin matrix appears to be the best system to fulfill the
criteria of realism, reliability, and safety needed for future
relevant clinical trials aimed at delivering growth factors. The
major handicap of in vivo gene transfer strategies detected in
this study was the uncertainty of the actual source and
number of the targeted cells after viral vector administration.
In a clinical context, this uncertainty may lead to misleading
conclusions that do not reliably reflect the actual outcome of
the trial. This was particularly the case in our hands when the
adenoviral vector was administered as a suspension by
intradermal injection. The production of transduced fibro-
blasts by ex vivo infection offers the possibility to verify
not only the transduction efficiency of the cells before
treatment but also the exact amount of protein produced, an
important advantage of this technique. In addition, the
number of cells embedded in the fibrin gel and their precise
location are easily subjected to therapeutic manipulation.
Also, the source of fibroblasts is a tissue derived from routine
outpatient biopsy that readily regenerates the donor site with
minimal morbidity. Fibroblasts are, in addition, easy to
isolate, cultivate, and transduce, and are capable of secreting
a broad range of therapeutically useful proteins (Krebsbach
et al., 2000). In the particular case of KGF, fibroblasts are the
natural source of the protein that acts in a paracrine manner
KGF
Human skin Human skin
KGF
GFP
KGF
Day 6 Day 12
GFP
KGF KGF
Figure 5. Enhancement of the closure of a wound by application of fibrin gel
containing ex vivo adenovirus-transduced fibroblasts overexpressing KGF.
(a) Phase-contrast and fluorescence microscopy images of a human fibroblast
primary culture ex vivo transduced by the Ad-KGFiresGFP vector, 24 hours
after viral infection (left and right panel, respectively). Bar¼ 0.5mm.
(b) Phase-contrast and fluorescence microscopy images of a fibrin gel
containing 106 human fibroblasts transduced by the Ad-KGFiresGFP vector
(left and right panel, respectively), 24 hours after viral infection and 2 hours
after fibrin gel assembly following the same procedure as described in
Figure 3. Note that 2 hours after embedding in the fibrin gel, fibroblasts show
a round shape. Bar¼0.5 mm. (c) Stereo-microphotographs of a 3-day wound
treated with a fibrin gel containing 106 adenovirus-transduced fibroblasts,
after Tegaderm has been removed, under white light illumination (left panel)
and epifluorescence illumination (right panel). GFP fluorescence is restricted
to fibroblasts embedded in the fibrin gel. Dotted white lines delimit the
wound edge. Bar¼ 0.5mm. (d and e) H&E staining (composite picture) of the
wound center of animals treated with fibrin gels containing Ad-GFP- and
Ad-KGFiresGFP-transduced fibroblasts at 3, 6, and 12 days post-wounding.
Black lines underline the basal epidermal layer and the migratory tongue.
KGF protein delivery from gel-embedded transduced fibroblasts accelerates
the wound re-epithelialization as evidenced by a reduction of the epidermal
gap distance (delimited by a double arrowhead) at 3 and 6 days.
Bar¼0.5mm. H&E¼hematoxylin and eosin.
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Figure 6. Cell proliferation analysis in 3-day wounds overexpressing KGF
corresponding to different gene targeting strategies assessed by BrdU
immunostaining. (a) Retrovirally transduced skin used as a reference (GFP-tg
and KGF-tg skin). (b) In vivo transduction by injection of adenoviral vector
suspension. (c) In vivo transduction by adenoviral vector using fibrin as a
carrier. (d) Ex vivo transduced fibroblasts embedded in fibrin gels. The
proliferation index was calculated as the % of the BrdU-positive nuclei in the
first 100 basal keratinocytes of the two opposite tongues (excluding the
migratory tip) and the following 100 cells of the margin. Both the tongue and
the surrounding margin of wounds that overexpress KGF exhibited a
statistically significant (Po0.05) increase in the proliferation index for the
three different strategies tested.
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on keratinocytes. Thus, the fibroblast approach most likely
allows a more appropriate presentation of the growth factor.
Finally, the use of ex vivo targeted cells circumvents direct
exposure of the patient to viral vectors, a major safety
concern in human trials when adenoviral vectors are
administered either systemically or locally (Yang et al.,
1995; Molnar-Kimber et al., 1998; Roth et al., 1998; Sterman
et al., 1998; Gu et al., 2004; Margolis et al., 2004). In spite of
all these advantages, the use of immobilized adenoviral
vectors would appear the best alternative when wound-
promoting molecules such as transcription factors or cell
signaling molecules are to be delivered.
In conclusion, we show that growth factor delivery to
humanized wounds, through ex vivo adenovirus-targeted
fibroblasts embedded in a fibrin matrix, avoids the uncertain-
ties of in vivo cell targeting. The use of this system avoids the
potential danger of scoring cases of faulty administration,
such as therapeutic failures as well as direct patient exposure
to viral vectors. The technique also offers the possibility of
delivering biologically active proteins in a sustained manner
(throughout the tested period), thus increasing the chances of
therapeutic success, particularly within a protein-hostile
environment often found in chronic wound beds.
MATERIALS AND METHODS
Animals
Immunodeficient Rj: NMRI—Foxn1nu (NMRI nu) mice (6–8 weeks
old) were used (Elevage Janvier, Le Genest Saint Isle, France). Mice
were housed for the duration of the experiment at the CIEMAT
Laboratory Animals Facility (Spanish registration number 28079-21
A) in pathogen-free conditions using micro-isolators, individually
ventilated cages type IIL, at a maximum of six mice per cage, with 25
air cage changes per hour and heat-treated soft wood pellets as
bedding. All experimental procedures were carried out according to
the European and Spanish laws and were in keeping with regulations
on the protection and use of animals in scientific research.
Procedures were approved by our Animal Experimentation Ethical
Committee according to all external and internal biosafety and
bioethics guidelines.
Retroviral vector preparation
The hKGF cDNA was obtained by reverse transcriptase-PCR
technique using total mRNA from human fibroblasts. The following
oligonucleotides were employed in the amplification reaction:
forward: 50-CACCCGGAGCACTACACTATA-30; reverse: 50-CCACT-
TAAAGAAATCTCCCTG-30. The sequence was confirmed using
standard DNA sequencing methods. The bicistronic pLZR-KGF-
ires-GFP recombinant replication-deficient retroviral vector (Figure 1a)
was constructed using a partial digestion strategy to place the hKGF
cDNA in the EcoR1 cloning site of the pLZR-ires-GFP vector (Larcher
et al., 2001). The same vector without hKGF cDNA was used to
generate control transgenic skin. These retroviral vectors were used
to produce PA317-derived stable packaging cell lines for ex vivo
keratinocyte infection.
Adenoviral vector preparation
Construction and purification of the viral vector was performed as
we described previously (Carretero et al., 2004, 2008). The KGF
bicistronic serotype 5 replication-defective adenovirus vector
containing the cytomegalovirus promoter was produced by conven-
tional homologous recombination (Figure 2a). To construct the
Ad-KGFiresGFP vector, the hKGF cDNA was cloned along with an
ires-GFP expression cassette (Clontech, Palo Alto, CA) in pDC315
shuttle vector (Microbix Biosystems Inc., Toronto, ON, Canada). The
recombinant adenoviral vectors were generated by co-transfection of
the shuttle vector along with pBHGloxDE1.3Cre in 293 cells
(Microbix Biosystems Inc.), using the calcium phosphate transfection
method. Plaques were isolated and expanded, and viral DNA was
extracted and analyzed by HindIII restriction enzyme digestion as
described previously (Graham and van der Eb, 1973). Adenoviruses
were propagated in 293 cells, purified by double CsCl density
centrifugation (Graham and Prevec, 1995), and stored at 70 1C in
10mM Tris/1mM MgCl2, pH 7.8, containing 10% glycerol. Viral titers
were determined by end-point dilution assay, applying serial
dilutions of the purified viruses to 293 cells. Tissue culture infectious
dose 50 was calculated and the cytopathic effect was evaluated after
14 days (violet crystal). Ad-GFP was kindly provided by Dr David T
Curiel (University of Alabama, Birmingham, AL).
Primary cultures of human keratinocytes and fibroblasts
Human keratinocytes and dermal fibroblasts were isolated from skin
biopsies obtained from donors (Rheinwald and Green, 1975).
Cultures were established following ethical approval and informed
consent. The study was conducted according to the Declaration of
Helsinki Principles. Primary keratinocytes were cultured on a feeder
layer of lethally irradiated (X-ray; 50Gy) 3T3-J2 cells (a gift from Dr J
Garlick, SUNY, Stony Brook, NY) as described previously (Meana
et al., 1998; Del Rio et al., 2002). The keratinocyte seeding medium
was a 3:1 mixture of DMEM (Gibco-BRL, Barcelona, Spain) and
HAM’S F12 (Gibco-BRL) containing 10% fetal calf serum, 0.1 nM
choleric toxin, 2 nM T3, 5mgml1 insulin, 0.4mgml1 hydrocorti-
sone, and 10 ngml1 EGF (Sigma, St Louis, MO). Primary fibroblasts
were cultured on plastic in DMEM containing 10% fetal calf serum.
Cells were cultured at 37 1C in a humid atmosphere containing 5%
CO2. The culture medium was changed every 2 days.
Wounding of KGF-tg human skin
Wound healing experiments were performed, as previously de-
scribed (Escamez et al., 2004), on nude mice orthotopically grafted
(Del Rio et al., 2002) with bioengineered human skin equivalent
based on a fibrin matrix containing live fibroblasts as a dermal
component and keratinocytes stably expressing KGF as the
epidermal component (Figure S1a). Primary human keratinocytes
were stably transduced by two cycles of 6 hours exposure to 24 hours
supernatants from the packaging cell line PA317 (ATCC, Manassas,
VA) that produces amphotropic retroviral particles containing either
the pLZR-ires-GFP or pLZR-KGF-ires-GFP. At 12 weeks after grafting,
GFP-tg- and KGF-tg-regenerated human skins were excisionally
injured with 2mm biopsy punches (Stiefel Lab, Offenbach,
Germany). Genetically modified human skin grafts were detected
by GFP fluorescence in the intact xenograft using a stereomicroscope
with adequate illumination filters (Olympus, Barcelona, Spain).
Permanently KGF/GFP-expressing human skin obtained through
ex vivo retroviral gene transfer (KGF/GFP-tg human skin) was used as
a reference for the in vivo adenovirus-mediated KGF delivery
approaches.
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Wound KGF delivery approaches
Wound healing experiments were performed, as previously de-
scribed (Escamez et al., 2004), on nude mice orthotopically grafted
with bioengineered human skin equivalents (Del Rio et al., 2002). At
12 weeks after transplantation, engrafted human skin was excision-
ally injured with 2mm biopsy punches (Stiefel Lab). At this point,
three adenovirus-mediated KGF delivery approaches were used to
treat the wounds (Figure S1b):
1. The in vivo gene delivery approach by adenoviral vector
suspension was performed via intradermal injection of a volume
of 50 ml containing 3 109 PFU of either Ad-GFP or Ad-
KGFiresGFP applied via three separate injections around the
wound edge. A total of 24 animals were used and gene transfer
was confirmed in 14 animals on days 1 and 3 post-wounding by
detection of GFP fluorescence in the wounded skin.
2. The in vivo gene delivery approach involved immobilization of
the adenoviral vector in a fibrin gel. To prepare the fibrin gel,
3 109 PFU of Ad-GFP or Ad-KGFiresGFP was added to 3ml of
DMEM containing 10% fetal calf serum, 750 ml of fibrinogen
solution at 1mgml1, and 2.75 IU of bovine thrombin in 250ml
0.025mM CaCl2 (Sigma). A 500ml portion of the mixture
containing a total concentration of 0.5mgml1 of fibrinogen
was placed in every well of a 24-well plate and allowed to
solidify for 30minutes at 37 1C in a humid atmosphere contain-
ing 5% CO2. A total of 29 animals were treated by covering the
2mm wounds and the surrounding area with gels containing
either Ad-GFP or Ad-KGFiresGFP, which were held in place
with a piece of adhesive Tegaderm (3M Health Care, St Paul,
MN) (Figure 3a). Gene transfer was confirmed in 20 animals on
day 3 post-wounding by detection of GFP fluorescence.
3. The in vivo protein delivery involved ex vivo adenoviral gene
transfer of fibroblasts. Primary human fibroblasts were infected
with adenoviral purified vectors (of Ad-GFP or Ad-KGFiresGFP)
for 6 hours at 37 1C in a humid atmosphere containing 5% CO2
at a multiplicity of infection of 50 (Figure 5a). The medium
containing adenoviruses was discarded and fresh medium was
added to transduced cells; 24 hours later, 106 Ad-GFP- or Ad-
KGFiresGFP-transduced fibroblasts were embedded in fibrin
gels (750 ml of fibrinogen) prepared as described above (Figure
5b). Four hours after clotting, gels containing Ad-GFP- or Ad-
KGFiresGFP-transduced fibroblasts were applied covering the
2mm wounds and the surrounding area and held in place with a
piece of adhesive Tegaderm (3M Health Care). A total of 16
animals were treated, and in all cases the persistence of
transgene expression in fibroblasts was observed on day 3
post-wounding by detection of GFP fluorescence on the
wounded skin.
Sample collection and histological processing
Three days post-wounding, mice were euthanized by CO2 asphyxia-
tion. Rectangular samples of skin containing the wounds were
harvested, fixed in 3.7% formaldehyde, and embedded in paraffin.
Serial 4mm cross-sections were obtained. The whole sample was
sectioned and 1 of every 10 sections was stained with hematoxylin–-
eosin (Gill 2 Hematoxylin and Eosin Y alcoholic; Thermo Shandon,
Darmstadt, Germany) following standard procedures to determine
the center of the wound and to adequately monitor the healing
process. Six- and 12-day wounds were also collected in the case of
in vivo protein delivery through the ex vivo gene-transferred
fibroblasts approach.
Protein extraction and hKGF quantitation
Tissue samples were collected from the same animal (ex vivo
retroviral keratinocyte transduction) or from matched animals when
the in vivo adenoviral transduction (suspension and immobilized)
and ex vivo adenoviral fibroblast transduction strategies were
assessed. Samples were frozen in liquid nitrogen and stored at
80 1C until further analysis. Total protein was extracted from tissue
samples, homogenized in a solution consisting of 1.0 M NaCl, 20mM
Tris–HCl (pH 7.4), 5mM EDTA, 2% Triton X-100, 1mM phenyl-
methylsulfonyl fluoride, and 10 pgml1 aprotinin–leupeptin, and
cleared by centrifugation at 10,000 r.p.m. for 40minutes at 4 1C. The
protein content in the supernatants was measured (Bio-Rad protein
assay; Bio-Rad, Madrid, Spain) and all samples were adjusted to a
uniform concentration before the assay.
Supernatants (2ml) were recovered after 24 hours from fibrin
gels containing 106 fibroblasts transduced either with Ad-GFP or
Ad-KGF.
ELISA immunodetection was used to confirm delivery of KGF
protein to the wound in treated tissue samples compared to controls,
as well as in fibrin gel supernatants containing transduced
fibroblasts. ELISA was carried out following the manufacturer’s
recommendations (Quantikine human KGF immunoassay; R&D
System, Minneapolis, MN). Putative induction of KGF protein in
control wounds appeared to be below the detection levels at this
time point.
Immunostaining
Formaldehyde-fixed paraffin sections were dewaxed by melting for
30–60minutes at 601C, cleared in xylene three times for 5minutes,
and rehydrated in water solutions containing decreasing percentages
of ethanol. To establish the human origin of the regenerated skin,
human-specific antibodies against involucrin and vimentin were
used to label human keratinocytes and human fibroblasts, respec-
tively. The human-specific mAbs were used at a final dilution of
1:100 for involucrin (clone SY5; Sigma-Aldrich, St Louis, MO) and
1:50 for vimentin (V9; Biogenex, San Ramon, CA). GFP immuno-
peroxidase staining was performed using specific polyclonal
antibodies anti-GFP (clone A-11122; Molecular Probes, Eugene,
OR) at a 1:200 dilution. Cell proliferation was assessed through
immunoperoxidase detection of BrdU incorporation using an anti-
BrdU antibody at a 1:50 dilution (Roche Molecular Biochemical,
Barcelona, Spain). Previously, grafted mice were intraperitoneally
injected with 20mg kg1 of BrdU 1hour before killing (BrdU; Roche
Molecular Biochemical, Barcelona, Spain). All immunoperoxidase
stainings were performed with standard procedures using the
Vectastain ABC kit (Vector, Burlingame, CA).
Wound healing analysis
The performance of the three different strategies of hKGF delivery
through adenovirus-mediated gene transfer was compared in terms
of successfully transduced animals, re-epithelialization, and prolif-
eration index in healing of 2mm wounds in the humanized skin at
3 days post-wounding.
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The analysis of wound contraction in human and murine wounds
was performed by taking stereo-microphotographs from 2mm
wounds made in nu/nu mice skin or engrafted human skin (nu/nu
mice) at 0 hour and 24 hours post-wounding and measuring the
wound area using Scion Image software (Scion Corporation,
Frederick, MD). The percentage of wound contraction was
calculated by the following formula: 100[(wound area at
0 hourwound area at 24 hours)/wound area at 0 hour]. Values
were expressed as mean±SD.
The re-epithelialization across each wound site was analyzed by
light microscopy (Olympus) using a reticule to measure the proportion
of each wound that was covered by neoepidermis in relation to the
entire wound length (Staiano-Coico et al., 1993; Pierce et al., 1994).
Re-epithelization was assessed through the measure of the epidermal
gap (the distance between opposite epithelial tongues) and the direct
measure of migrating epithelial tongues. The percentage of wound
closure was calculated by the following formula: 100[(wound
diameterepidermal gap)/wound diameter]. Values were expressed
as mean±SD. The length of the epithelial migratory tongue was
expressed as mean±SD in mm. The analysis of re-epithelialization
was performed only using the successfully targeted wounds.
The proliferation index was calculated as the % of the BrdU-
positive nuclei in the first 100 basal keratinocytes of the two opposite
tongues (excluding the migratory tip) and the following 100 cells of
the margin. Results were expressed as mean±SD. The increase in
the proliferation index was calculated as the ratio between the % of
total BrdU-positive nuclei (% of total BrdU-positive nuclei in the
tongueþ% of total BrdU-positive nuclei in the margin) in control
and treated animals. The analysis was performed using only the
successfully targeted wounds.
Statistical analysis
A two-tailed Student’s t-test was applied to compare the means
of samples using Microsoft Excel (Microsoft, Redwood, CA).
Differences were considered statistically significant when Po0.05.
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